Real-world impact of fremanezumab on migraine-related health care utilization and costs in patients with common comorbidities, acute medication overuse, or difficult-to-treat migraine

被引：0
|
作者：
Buse, D. C. [1 ,2 ]
Driessen, M. T. [3 ]
Krasenbaum, L. J. [4 ]
Seminerio, M. J. [5 ,6 ]
Carr, K. [5 ]
Ortega, M. [5 ]
Packnett, E. R. [7 ]
机构：
[1] Albert Einstein Coll Med, Dept Neurol, New York, NY USA
[2] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA
[3] Teva Pharmaceut, Amsterdam, Netherlands
[4] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA
[5] Teva Pharmaceut, Parsippany, NJ USA
[6] Teva Pharmaceut, W Chester, PA USA
[7] IBM Watson Hlth, Cambridge, MA USA
来源：
HEADACHE | 2022年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-91
引用
收藏
页码：80 / 81
页数：2
相关论文
共 50 条
  • [31] Impact of Fremanezumab Treatment on Clinical Outcomes Among Migraine Patients With Comorbid Depression, Anxiety or Hypertension in a Real-World Setting
    Tangirala, K.
    Pedarla, V.
    Driessen, M.
    Krasenbaum, L. J.
    Thompson, S. F.
    Maughn, K.
    Seminerio, M. J.
    Cohen, J. M.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 114 - 114
  • [32] Impact of Fremanezumab Treatment on Clinical Outcomes Among Migraine Patients With Comorbid Depression, Anxiety or Hypertension in a Real-World Setting
    Tangirala, K.
    Pedarla, V.
    Driessen, M.
    Krasenbaum, L. J.
    Thompson, S. F.
    Maughn, K.
    Seminerio, M. J.
    Cohen, J. M.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 169 - 169
  • [33] Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study
    Antoinette MaassenVanDenBrink
    Gisela M. Terwindt
    Joshua M. Cohen
    Steve Barash
    Verena Ramirez Campos
    Maja Galic
    Xiaoping Ning
    Mikko Kärppä
    The Journal of Headache and Pain, 2021, 22
  • [34] Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study
    MaassenVanDenBrink, Antoinette
    Terwindt, Gisela M.
    Cohen, Joshua M.
    Barash, Steve
    Campos, Verena Ramirez
    Galic, Maja
    Ning, Xiaoping
    Karppa, Mikko
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [35] RELATIVE FREQUENCY, HEALTHCARE RESOURCE UTILIZATION, AND COSTS OF DIAGNOSED DRUG-INDUCED HEADACHE AND POTENTIAL ACUTE MEDICATION OVERUSE IN PATIENTS WITH MIGRAINE
    Shewale, A.
    Brandenburg, J.
    Burslem, K.
    Lipton, R.
    Doshi, J.
    VALUE IN HEALTH, 2022, 25 (07) : S395 - S395
  • [36] Relative frequency, healthcare resource utilization, and costs of diagnosed drug-induced headache and potential acute medication overuse in patients with migraine
    Shewale, A. R.
    Brandenburg, J. A.
    Burslem, K.
    Lipton, R. B.
    Doshi, J. A.
    HEADACHE, 2022, 62 : 84 - 84
  • [37] Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study
    Stewart J. Tepper
    Juanzhi Fang
    Pamela Vo
    Ying Shen
    Lujia Zhou
    Ahmad Abdrabboh
    Mrudula Glassberg
    Matias Ferraris
    The Journal of Headache and Pain, 2021, 22
  • [38] Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study
    Tepper, Stewart J.
    Fang, Juanzhi
    Vo, Pamela
    Shen, Ying
    Zhou, Lujia
    Abdrabboh, Ahmad
    Glassberg, Mrudula
    Ferraris, Matias
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [39] Impact of fremanezumab on any acute headache medication use in migraine patients with medication overuse and documented inadequate response to 2-4 migraine preventive medications in the multicentre, randomised, placebo-controlled FOCUS study
    Newman, Lawrence
    Cohen, Joshua M.
    Ramirez-Campos, Verena
    Janka, Lindsay
    Diener, Hans-Christoph
    CEPHALALGIA, 2019, 39 : 238 - 238
  • [40] HEALTH CARE RESOURCE UTILIZATION AND COSTS IN A SAMPLE OF REAL-WORLD PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA
    Grabner, M.
    Higuchi, K.
    Ramey, N.
    Toth, P.
    VALUE IN HEALTH, 2014, 17 (03) : A110 - A110
12345